NCT03852251: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

NCT03852251
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Ph+ase Ib Cohort 1
Exclusions: Patients with central nervous system (CNS) metastasis, meningeal metastasis, spinal cord compression, or leptomeningeal disease.
https://ClinicalTrials.gov/show/NCT03852251

Comments are closed.

Up ↑